C/M Capital Master Fund, LP 13D and 13G filings for Biodexa Pharmaceuticals Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-28 5:59 pm Purchase | 2025-05-20 | 13G | BIODEXA PHARMACEUTICALS INC SP BDRX | C/M Capital Master Fund, LP | 35,047,800 6.800% | 35,047,800 (New Position) | Filing |
| 2025-02-18 4:30 pm Unchanged | 2025-02-10 | 13G | BIODEXA PHARMACEUTICALS INC SP BDRX | C/M Capital Master Fund, LP | 0 0.000% | 0 (Unchanged) | Filing |